The BCL-2 family of anti-apoptotic proteins, such as BCL-xL, BCL-2, and MCL-1, represent promising therapeutic targets for SCLC, a malignancy characterized by its aggressive nature and resistance to standard treatment modalities [1,2,3,4,12,13,14,15]. Here, BCL2L1 is linked to small cell lung carcinoma.